Application of Iron Oxide Nanoparticles in the Preparation of Drugs for Improving Erlotinib Resistance

A technology of iron oxide nanometer and drug resistance, which is applied in the direction of drug combination, antineoplastic drug, bulk delivery, etc., can solve drug resistance and other problems, achieve high biological safety, far-reaching clinical significance and promotion, and enhance anti-tumor The effect of cell proliferation
CN105055447BActive Publication Date: 2018-03-13THE SECOND XIANGYA HOSPITAL OF CENT SOUTH UNIV
3 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
THE SECOND XIANGYA HOSPITAL OF CENT SOUTH UNIV
Publication Date
2018-03-13

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The present invention discloses applications of iron oxide nanoparticles in preparation of a drug for improving erlotinib resistance, wherein a mass ratio of the iron oxide nanoparticles to the erlotinib is generally 1-40:1 and the consumption of the iron oxide nanoparticles in each day is not more than 10 mg / kg when the iron oxide nanoparticles are used for preparing the drug for improving erlotinib resistance. According to the present invention, lung cancer cells H 358 cultured in vitro and a drug resistance cell line A549 cultured in vitro are concurrently treated with the iron oxide nanoparticles and the erlotinib, and the results show that the anti-tumor-cell-proliferation effect can be significantly enhanced; further experiment results show that the tumor growth can be significantly inhibited through the combination of the iron oxide nanoparticles and the erlotinib, such that it is suggested that the iron oxide nanoparticles can enhance the sensitivity of the lung cancer cells on the erlotinib through the ERBB2, ERBB3, ERBB4 downstream signaling pathway; and the solving scheme is provided for the clinical treatment of the erlotinib resistant lung cancer patient.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the new pharmaceutical application of substances, in particular to the application of iron oxide nanoparticles in the preparation and improvement of drug resistance. Background technique

[0002] Lung cancer is the most common malignant tumor in my country, and molecular targeted therapy is a new way to treat lung cancer. Erlotinib (English: Erlotinib) is currently the first-line targeted therapy for advanced non-small cell lung cancer, which significantly prolongs the survival of patients. Erlotinib has different therapeutic effects in different patients, and its key molecular marker is epidermal growth factor receptor (EGFR). In a study known as IPASS (EGFR Inhibitors Pan-Asian Study), EGFR small-molecule inhibitors were significantly superior to standard chemotherapy in the first-line treatment of patients with advanced EGFR mutation-positive lung adenocarcinoma, compared with EGFR mutation-negative patients. Inhibitors we...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More